Joint Workshop to Address Lack of Drug-Radiotherapy Combinations

The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as multiple myeloma and metastatic melanoma, are turning into chronic diseases due to the use of novel, targeted systemic therapies. Immunotherapy is altering the natural history of certain malignancies.

Read More

FDA Approves Targeted Radiotherapy for Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients with neuroendocrine tumors. The new therapeutic—lutetium (Lu) 177 dotatate (Lutathera)—is a targeted form of systemic radiotherapy.

Read More

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain patients with metastatic, HER2-negative breast cancer. The FDA also granted marketing authorization for a test to identify those patients eligible to receive olaparib: patients with an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Biosimilars: Breaking Through to Cancer Treatment

A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical therapies has recently borne fruit for the cancer community in the form of two new therapeutic options for a wide range of cancers—bevacizumab-awwb (Mvasi) and trastuzumab-dkst (Ogivri).

Read More

Vemurafenib Becomes First FDA-approved Treatment for a Rare Type of Blood Cancer

Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults who have a rare type of blood cancer called Erdheim-Chester disease. Vemurafenib targets mutant forms of the protein BRAF, and it has been approved for treating those patients whose Erdheim-Chester disease harbors the BRAF V600 mutation.

Read More